Pediatrics – Infectious Diseases
M-A | A short course of antibiotics is noninferior to long-course therapy in children with nonsevere pneumonia.
16 Nov, 2022 | 13:43h | UTCShort-Course vs Long-Course Antibiotic Therapy for Children With Nonsevere Community-Acquired Pneumonia: A Systematic Review and Meta-analysis – JAMA Pediatrics (free for a limited period)
Commentary: Review: Shorter antibiotic course sufficient for kids with pneumonia – CIDRAP
Related:
ACP Guidance: Appropriate Use of Short-Course Antibiotics in Common Infections
RCT: 7 days of antibiotic therapy as good as 14 days for afebrile men with urinary tract infection.
Meta-Analysis: Efficacy of Short-Course Antibiotic Treatments for Community-Acquired Pneumonia
Editorial | The urgent need to recognize and properly address prenatal-onset group B Streptococcus disease.
10 Nov, 2022 | 13:59h | UTC
Cohort Study | Covid-19 vaccine effectiveness among children and adolescents in Qatar.
4 Nov, 2022 | 13:51h | UTC
Commentary on Twitter
The 10-µg dose of BNT162b2 led to modest, rapidly waning protection against Covid-19 in children 5 to 11 years old. The 30-µg dose in adolescents gave greater, more durable protection; more so in 12-to-14-year-olds than in 15-to-17-year-olds. https://t.co/ddcqiR8jvO pic.twitter.com/M8oSFYoFlw
— NEJM (@NEJM) November 2, 2022
RCT | Evaluation of mRNA-1273 vaccine in children 6 months to 5 years of age.
20 Oct, 2022 | 12:35h | UTC
Commentary on Twitter
Randomized, placebo-controlled trial of the 2-dose @moderna_tx vaccine in children 6 months to 5 years, during Omicron. Safe in ~4,800 kids; good immune response; efficacy vs infections 👇https://t.co/DkLXAQQaeZ @NEJM pic.twitter.com/ettWOnDGQf
— Eric Topol (@EricTopol) October 19, 2022
Myocarditis after BNT162b2 vaccination in Israeli adolescents.
20 Oct, 2022 | 12:34h | UTCMyocarditis after BNT162b2 Vaccination in Israeli Adolescents – New England Journal of Medicine
Commentary on Twitter
Among Israeli adolescents between 12 and 15 years of age who received the BNT162b2 vaccine, 9 cases of mild myocarditis were observed, mainly after the second dose. https://t.co/OatYqN4IPD pic.twitter.com/c96d1o7wnt
— NEJM (@NEJM) October 19, 2022
Cohort Study | New and progressive medical conditions after pediatric sepsis hospitalization requiring critical care.
13 Oct, 2022 | 13:45h | UTCNew and Progressive Medical Conditions After Pediatric Sepsis Hospitalization Requiring Critical Care – JAMA Pediatrics (free for a limited period)
Commentary on Twitter
The development or progression of comorbid conditions occurred in over 10% of children who survived #sepsis hospitalization, suggesting that they may benefit from structured follow-up to identify and address new or worsening medical conditions. https://t.co/yfAt60PsU6
— JAMA Pediatrics (@JAMAPediatrics) October 11, 2022
RCT | Topical antibiotics reduce the time to clinical cure in children with infective conjunctivitis.
5 Oct, 2022 | 13:55h | UTCCommentaries:
Topical Antibiotics Shorten Duration of Conjunctival Symptoms – HealthDay
Commentary on Twitter
In this RCT and meta-analysis with 3 prior RCTs, children who received antibiotic eye drops had shorter duration of conjunctivitis vs. placebo. #OAResearch https://t.co/3mq5Fr8NDS
— JAMA Network Open (@JAMANetworkOpen) October 4, 2022
AAP Clinical Report | Controlling and treating head lice in children and adolescents.
3 Oct, 2022 | 14:04h | UTC
Systematic Review | Home care for bronchiolitis.
21 Sep, 2022 | 13:14h | UTCHome Care for Bronchiolitis: a Systematic Review – Pediatrics
Commentary on Twitter
Given the growing interest in and potential impact of the Hospital-at-Home model, this review helps determine whether bronchiolitis requiring hospital-level care is feasible, acceptable to families, and can be safely managed in the home: https://t.co/eISjhYmRdd #Pediatrics pic.twitter.com/qjJYSDUTOq
— AAP Pediatrics (@aap_peds) September 6, 2022
Impact of routine childhood immunization in reducing vaccine-preventable diseases in the US.
21 Sep, 2022 | 13:11h | UTC
RCT | Among neonates with probable bacterial infection, switching from intravenous to oral antibiotics (amoxicillin–clavulanic acid) was noninferior to a full course of intravenous antibiotics and resulted in shorter hospitalization (median duration of 3.4 vs. 6.8 days).
16 Sep, 2022 | 12:59h | UTCEfficacy and safety of switching from intravenous to oral antibiotics (amoxicillin–clavulanic acid) versus a full course of intravenous antibiotics in neonates with probable bacterial infection (RAIN): a multicentre, randomised, open-label, non-inferiority trial – The Lancet Child & Adolescent Health (link to abstract – $ for full-text)
Commentary: Dutch team devise less painful ‘drip and drink’ antibiotics treatment for babies – Dutch News
Commentaries on Twitter
*New trial*—early switch to #OralAntibiotics is not inferior to full-course IV antibiotics in #neonates with probable bacterial infection; & adverse events were not increased with use of oral antibiotics
By @IKMReiss @karelallegaert & colleagues
https://t.co/2yzeh3ptuc pic.twitter.com/BgBosxfECC
— The Lancet Child & Adolescent Health (@LancetChildAdol) September 12, 2022
In term and near-term infants <28 days with probable bacterial infection, how safe is it to switch to oral Amox-Clav as opposed to completing a course of intravenous antibiotics? A new RCT in @Lancet tries to answer this question.https://t.co/M2Za54cfxF#EBNeoAlerts#NeoEBM pic.twitter.com/zKpIiW1Whx
— Evidence-Based Neo (@EBNEO) September 12, 2022
(Thread – click for more)
Efficacy & safety of switching from intravenous to oral antibiotics (amoxicillin–clavulanic acid) vs full course of IV antibiotics in neonates with probable bacterial infection (RAIN):multicentre, randomised,open-label,non-inferiority trial -The Lancet https://t.co/mcyr9bILRq
— Prof. Dr. Sanjeev Bagai (@BagaiDr) September 13, 2022
Global, regional, and national burdens of HIV and other sexually transmitted infections in adolescents and young adults aged 10–24 years from 1990 to 2019: a trend analysis based on the Global Burden of Disease Study 2019.
16 Sep, 2022 | 12:50h | UTCGlobal, regional, and national burdens of HIV and other sexually transmitted infections in adolescents and young adults aged 10–24 years from 1990 to 2019: a trend analysis based on the Global Burden of Disease Study 2019 – The Lancet Child & Adolescent Health (link to abstract – $ for full-text)
Commentary on Twitter
New analysis of #GBD data reports the global incidence of #HIV and other #STIs in adolescents and young adults https://t.co/hSjgHMGg4R pic.twitter.com/JBd7Goa9Sa
— The Lancet Child & Adolescent Health (@LancetChildAdol) September 13, 2022
Review | Multisystem inflammatory syndrome in children (MIS-C) and neonates (MIS-N) associated with COVID-19: optimizing definition and management.
14 Sep, 2022 | 13:15h | UTC
Commentary on Twitter
Proposed classification of Multisystem inflammatory syndrome in #neonates (MIS-N)
Clinical features
Treatment and immunological mechanisms#MISC #covid19 #PIMSTS #PedsICU#NeoEBM @DrSBagci #NeoTwitter #Neonatology @DrKenRemy1 @ChrisCarrollMD @lizWWyld https://t.co/tDuM51GMr4 pic.twitter.com/PNobOOzevX— Yonca Bulut M.D. (@yoncabulutmd) September 6, 2022
Under a http://creativecommons.org/licenses/by/4.0/ License
M-A | Antibiotic use in ambulatory care for acutely ill children in high-income countries.
14 Sep, 2022 | 13:10h | UTC
Review | COVID-19 in children.
8 Sep, 2022 | 14:43h | UTCCOVID-19 in Children – Pediatric Clinics of North America
Once-daily dolutegravir-based antiretroviral therapy in infants and children living with HIV from age 4 weeks: results from the below 14 kg cohort in the randomized ODYSSEY trial.
8 Sep, 2022 | 14:33h | UTC
Commentary on Twitter
New: Once-daily dolutegravir-based antiretroviral therapy in infants and children living with HIV from age 4 weeks: results from the below 14 kg cohort in the randomised ODYSSEY trial by Pauline Amuge @bayloruganda and colleagues @MRCCTU https://t.co/mc1jWSXMU2 #openaccess pic.twitter.com/A10LgZcwjF
— The Lancet HIV (@TheLancetHIV) September 1, 2022
Pediatric infective endocarditis: a literature review.
8 Sep, 2022 | 14:31h | UTCPediatric Infective Endocarditis: A Literature Review – Journal of Clinical Medicine
Systematic Review | Probiotics for preventing acute upper respiratory tract infections.
6 Sep, 2022 | 14:40h | UTCProbiotics for preventing acute upper respiratory tract infections – Cochrane Library
Commentary on Twitter
#probiotics for preventing colds? @CochraneARI looked at 24 studies w 6,950 people.
👍 may be beneficial in preventing at least 1 occurrence of acute upper respiratory tract infection #URTI & likely beneficial in preventing 3 occurrences of URTIs.https://t.co/A6XxrjKKcI pic.twitter.com/mDR3NYLLzQ— The Cochrane Library (@CochraneLibrary) August 24, 2022
Consensus Statement | Cardiac screening prior to return to play after SARS-CoV-2 infection in the child and adolescent athlete. – “Asymptomatic individuals and those with mild symptoms should be cleared by their primary care or team physician, after physical examination and accurate evaluation of medical history”.
6 Sep, 2022 | 14:36h | UTC
M-A | Safety and efficacy of abacavir for treating infants, children, and adolescents living with HIV.
6 Sep, 2022 | 14:27h | UTC
Commentary on Twitter
*New meta-analysis* supports the use of #abacavir as a preferred first-line regimen for infants & children living with #HIV
By @jujesson & colleagueshttps://t.co/WSvp5ZOUf1 pic.twitter.com/qFBo5O3zJC
— The Lancet Child & Adolescent Health (@LancetChildAdol) September 5, 2022
Study Commentary | Zinc for the prevention or treatment of respiratory tract infections: a new systematic review.
1 Sep, 2022 | 11:46h | UTC
Monkeypox: a clinical update for pediatricians.
24 Aug, 2022 | 14:19h | UTCMonkeypox: A clinical update for paediatricians – Journal of Pediatrics and Child Health
Related:
CDC Report | Epidemiologic and clinical characteristics of Monkeypox cases in the US.
Update on the Monkeypox Outbreak – JAMA
WHO Declares Global Public Health Emergency Over Monkeypox Virus Outbreak – Health Policy Watch
Monkeypox: A Contemporary Review for Healthcare Professionals – Open Forum Infectious Diseases
WHO Guidance | Behavioral and social drivers of vaccination: tools and practical guidance for achieving high uptake.
22 Aug, 2022 | 12:13h | UTC
Retrospective cohort study | Risk of preterm birth, small for gestational age at birth, and stillbirth after covid-19 vaccination during pregnancy.
18 Aug, 2022 | 12:51h | UTCNews Release: No link between COVID-19 vaccination in pregnancy and higher risk of preterm birth or stillbirth – British Medical Journal
Related:
SARS-CoV-2 infection and COVID-19 vaccination in pregnancy – Nature Reviews Immunology
WHO Questions and Answers: COVID-19 vaccines and pregnancy.
COVID vaccines safely protect pregnant people: the data are in.
COVID-19 vaccination in pregnancy—number needed to vaccinate to avoid harm.
Editorial: Covid-19 treatments and vaccines must be evaluated in pregnancy.
AstraZeneca vaccination not linked to reduced fertility rates and adverse birth outcomes.
Study shows high effectiveness of the Pfizer mRNA COVID-19 vaccine in pregnancy.
5 Crucial Things to Know About COVID-19 Vaccines and Pregnancy.
CDC Guidance: Pregnant people should be vaccinated against COVID-19.
Cohort study: Pfizer/BioNTech COVID vaccine associated with 78% lower risk of Covid-19 in pregnancy.
Commentary on Twitter
No link between covid-19 vaccination in pregnancy and higher risk of preterm birth or stillbirth, finds study in @bmj_latesthttps://t.co/XLgFeoWVsp
Findings can help guide decision making about #covid-19 #vaccination during #pregnancy pic.twitter.com/9Pxm0Yv2Mf
— BMJ Group (@bmj_company) August 18, 2022
AAP Updated Clinical Report | The use of systemic and topical fluoroquinolones.
17 Aug, 2022 | 14:19h | UTCThe Use of Systemic and Topical Fluoroquinolones – Pediatrics